Evidence Hub

An Open-Label, Three Period, Fixed Sequence Study to Assess the Effect of a Single Dose of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Sildenafil in Healthy Subjects Under Fasting Conditions

ClinicalTrials.gov · COMPLETED, 2018

20 participants

Abstract

The purpose of this study is:

* To assess the effect of BIA 5 1058 400 mg on the pharmacokinetics (PK) of sildenafil.

* To assess the effect of sildenafil on the PK of BIA 5-1058.

Conditions: Pulmonary Arterial Hypertension.

Primary outcome: Cmax - Maximum observed concentration (for BIA 5-1058); Tmax - Time corresponding to occurrence of Cmax (for BIA 5-1058); T½ - Apparent terminal elimination half life (for BIA 5-1058); Cmax,ss - Maximum observed concentration at steady state (for sildenafi); Tmax,ss - Time corresponding to occurrence of Cmax,ss at steady state (for sildenafi); T½,ss - Apparent terminal elimination half-life at steady state (for sildenafi).

Enrollment: 20 participants.

How strong is the evidence?

Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 20 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free